Suppression of Toll-like receptor 4 activation by endogenous oxidized phosphatidylcholine, KOdiA-PC by inhibiting LPS binding to MD2

[1]  Chang Hoon Lee,et al.  Resolvins as new fascinating drug candidates for inflammatory diseases , 2012, Archives of Pharmacal Research.

[2]  S. Nam,et al.  MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity. , 2011, The Journal of infectious diseases.

[3]  S. Akira,et al.  Akt Contributes to Activation of the TRIF-Dependent Signaling Pathways of TLRs by Interacting with TANK-Binding Kinase 1 , 2011, The Journal of Immunology.

[4]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[5]  V. Bochkov,et al.  Generation and biological activities of oxidized phospholipids. , 2010, Antioxidants & redox signaling.

[6]  S. Kim,et al.  Hypoxic stress up‐regulates the expression of Toll‐like receptor 4 in macrophages via hypoxia‐inducible factor , 2010, Immunology.

[7]  J. F. Stevens,et al.  Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2). , 2010, Planta medica.

[8]  M. Kwak,et al.  Sulforaphane Suppresses Oligomerization of TLR4 in a Thiol-Dependent Manner , 2009, The Journal of Immunology.

[9]  S. Kim,et al.  Alteration of Toll-like receptor 4 activation by 4-hydroxy-2-nonenal mediated by the suppression of receptor homodimerization. , 2009, Chemico-biological interactions.

[10]  R. Jerala,et al.  Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation* , 2009, The Journal of Biological Chemistry.

[11]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[12]  D. Webb,et al.  Oxidized Phospholipid Inhibition of Toll-like Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4 , 2008, Journal of Biological Chemistry.

[13]  P. Pristovsek,et al.  MD‐2 as the target of curcumin in the inhibition of response to LPS , 2007, Journal of leukocyte biology.

[14]  A. Hermetter,et al.  Oxidized phospholipids: from molecular properties to disease. , 2007, Biochimica et biophysica acta.

[15]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[16]  J. Berliner,et al.  A role for neutral sphingomyelinase activation in the inhibition of LPS action by phospholipid oxidation products Published, JLR Papers in Press, June 14, 2006. , 2006, Journal of Lipid Research.

[17]  T. Arakawa,et al.  Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression , 2006, Hepatology.

[18]  R. Morris,et al.  Elevated autoantibodies against oxidized palmitoyl arachidonoyl phosphocholine in patients with hypertension and myocardial infarction. , 2005, Journal of autoimmunity.

[19]  K. Hirata,et al.  Oxidized Phosphatidylcholine in AlveolarMacrophages in Idiopathic Interstitial Pneumonias , 2005, Lung.

[20]  Y. Shoenfeld,et al.  Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus , 2003, Annals of the rheumatic diseases.

[21]  N. Sizemore,et al.  Reciprocal Modulation of Toll-like Receptor-4 Signaling Pathways Involving MyD88 and Phosphatidylinositol 3-Kinase/AKT by Saturated and Polyunsaturated Fatty Acids* , 2003, Journal of Biological Chemistry.

[22]  V. Bochkov,et al.  Anti-inflammatory properties of lipid oxidation products , 2003, Journal of Molecular Medicine.

[23]  J. Berliner,et al.  Specific Phospholipid Oxidation Products Inhibit Ligand Activation of Toll-Like Receptors 4 and 2 , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Witztum,et al.  Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells* , 2003, The Journal of Biological Chemistry.

[25]  S. Hazen,et al.  A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions* , 2002, Journal of Biological Chemistry.

[26]  F. Gruber,et al.  Protective role of phospholipid oxidation products in endotoxin-induced tissue damage , 2002, Nature.

[27]  J. Auwerx,et al.  Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-κB/IκB- and ERK2-dependent mechanisms , 2002 .

[28]  B. Binder,et al.  Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte‐Endothelial Interactions , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Hans Lee,et al.  Determinants of Bioactivity of Oxidized Phospholipids: Specific Oxidized Fatty Acyl Groups at the sn-2 Position , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Wei Sha,et al.  Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo * , 1997, The Journal of Biological Chemistry.

[31]  Ling Zhao,et al.  Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. , 2010, Nutrition reviews.

[32]  J. Berliner,et al.  A role for oxidized phospholipids in atherosclerosis. , 2005, The New England journal of medicine.

[33]  吉見 紀子.  Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias , 2004 .

[34]  J. Auwerx,et al.  Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms. , 2002, Cardiovascular research.